J Clin Psychopharmacol. 1983 Apr;3(2):133-9.
Journal of clinical psychopharmacology
K Rickels
PMID: 6132932
This article reviews the clinical literature of flurazepam, temazepam, and triazolam. The long half-life drug flurazepam and the short half-life drug triazolam produced similar results in terms of clinical improvement and adverse effects when equivalent dosages were administered. Temazepam, in the present U.S. formulation, appeared to be less effective in sleep latency than the other two compounds.